Zhen-Shu Xu (Zhenshu Xu)

Publication Activity (10 Years)

Years Active: 2020-2024
Publications (10 Years): 15

Top Topics

Histone Deacetylase

Municipal Solid Waste

Diffuse Large B Cell Lymphoma

Multiple Myeloma

Top Venues

Biomarker research

Experimental hematology & oncology

Cancer gene therapy

This page only lists publications with an associated author ORCID identifier.

Publications

Shufeng Xie, Hui Liu, Shouhai Zhu, Zhihong Chen, Ruiheng Wang, Wenjie Zhang, Huajian Xian, Rufang Xiang, Xiaoli Xia, Yong Sun, Jinlan Long, Yuanli Wang, Minghui Wang, Yixin Wang, Yaoyifu Yu, Zixuan Huang, Chaoqun Lu, Zhen-Shu Xu, Han Liu
Arsenic trioxide and p97 inhibitor synergize against acute myeloid leukemia by targeting nascent polypeptides and activating the ZAKα-JNK pathway. Cancer gene therapy (2024)
Wenjie Zhang, Sumei Li, Jinlan Long, Shufeng Xie, Minghui Wang, Han Liu, Zhen-Shu Xu
Novel CAR T-cell therapies for relapsed/refractory B-cell malignancies: latest updates from 2023 ASH annual meeting. Experimental hematology & oncology 13 (1) (2024)
Wenjie Zhang, Sumei Li, Jinlan Long, Shufeng Xie, Minghui Wang, Han Liu, Zhen-Shu Xu
Novel CAR T-cell therapies for relapsed/refractory B-cell malignancies: latest updates from 2023 ASH annual meeting. Experimental hematology & oncology 13 (1) (2024)
Wenjie Zhang, Sumei Li, Jinlan Long, Shufeng Xie, Minghui Wang, Han Liu, Zhen-Shu Xu
Novel CAR T-cell therapies for relapsed/refractory B-cell malignancies: latest updates from 2023 ASH annual meeting. Experimental hematology & oncology 13 (1) (2024)
Wenjie Zhang, Sumei Li, Chufeng Zhang, Zhengshuai Mu, Kaili Chen, Zhen-Shu Xu
Tumor-infiltrating lymphocytes predict efficacy of immunotherapy in advanced non-small cell lung cancer: a single-center retrospective cohort study. Acta oncologica (Stockholm, Sweden) (2023)
Wenjie Zhang, Jinlan Long, Peixia Tang, Kaili Chen, Guangyao Guo, Zezhong Yu, Jie Lin, Liping Liu, Rong Zhan, Zhen-Shu Xu
SYT7 regulates the progression of chronic lymphocytic leukemia through interacting and regulating KNTC1. Biomarker research 11 (1) (2023)
Shifen Wang, Xingyun Zhao, Siwen Wu, Dawei Cui, Zhen-Shu Xu
Myeloid-derived suppressor cells: key immunosuppressive regulators and therapeutic targets in hematological malignancies. Biomarker research 11 (1) (2023)
Shifen Wang, Xingyun Zhao, Siwen Wu, Dawei Cui, Zhen-Shu Xu
Myeloid-derived suppressor cells: key immunosuppressive regulators and therapeutic targets in hematological malignancies. Biomarker research 11 (1) (2023)
Shifen Wang, Xingyun Zhao, Siwen Wu, Dawei Cui, Zhen-Shu Xu
Myeloid-derived suppressor cells: key immunosuppressive regulators and therapeutic targets in hematological malignancies. Biomarker research 11 (1) (2023)
Hua Wang, Bi-Bo Fu, Zhi-Jun Wuxiao, Ya-Jun Li, Li Huang, Jie Ma, Zhi-Min Zhai, Jing Guo, Yuan-Bin Wu, Zhen-Shu Xu, Jia Feng, Sheng-Sheng Zhou, Ting-Ting Chen, Xing-Gui Chen, Guo-Wei Li, Ting-Zhi Liu, Hai-Bin Huang, Run-Hui Zheng, Yong-Hua Li, Hong-Fang Tao, Fu-Ming Zi, Fan Wu, Juan Wang, Hui Zeng, Cai-Bo Fu, Robert Peter Gale, Zhong-Jun Xia, Zhi-Wei Liang
A prognostic survival nomogram for persons with extra-nodal natural killer-/T-cell lymphoma. Leukemia 36 (11) (2022)
Ruiheng Wang, Shufeng Xie, Shouhai Zhu, Yong Sun, Bowen Shi, Dan Li, Ting Kang, Yuanli Wang, Zhen-Shu Xu, Han Liu
Targeting matrix metallopeptidase 2 by hydroxyurea selectively kills acute myeloid mixed-lineage leukemia. Cell death discovery 8 (1) (2022)
Pei-Xia Tang, Zhong-Zheng Zheng, Ke-Ming Du, Lin An, Zhen-Shu Xu
The novel HLA-DQB1*04:93 allele, identified by Sanger dideoxy nucleotide sequencing in a Chinese individual. HLA (2022)
Maolin Ge, Zhi Qiao, Yan Kong, Hongyu Liang, Yan Sun, Hui Lu, Zhen-Shu Xu, Han Liu
Modulating proteasome inhibitor tolerance in multiple myeloma: an alternative strategy to reverse inevitable resistance. British journal of cancer 124 (4) (2020)
Yiting Wang, Yong Wu, Zhen-Shu Xu, Huarong Zhou, Yuanzhong Chen, Rong Zhan
Cytogenetic abnormalities in patients with newly diagnosed multiple myeloma as a secondary primary malignancy: a retrospective study. Hematology (Amsterdam, Netherlands) 25 (1) (2020)
Maolin Ge, Dan Li, Zhi Qiao, Yan Sun, Ting Kang, Shouhai Zhu, Shifen Wang, Hua Xiao, Chunjun Zhao, Shuhong Shen, Zhen-Shu Xu, Han Liu
Restoring MLL reactivates latent tumor suppression-mediated vulnerability to proteasome inhibitors. Oncogene 39 (36) (2020)